Niagen Bioscience Matches On EPS, But A 20% Revenue Drop And Fading Guidance Push The Story To 2027

Niagen Bioscience delivered the loss Wall Street expected, posting a third-quarter loss of $0.01 per share, in line with the consensus estimate. The top line was the problem. Revenue of $27.19 million missed the $30.15 million consensus by 9.8% and fell 20.0% year over year. Earnings fell 120.0% from a year ago, a swing from a $4.6 million GAAP profit ($0.05 diluted) to a $1.2 million loss. The in-line EPS print does little to offset what was a broad deceleration. Sales, margins and profitability all moved the wrong way, and management is asking investors to look through 2026 toward a stack of catalysts that do not arrive until 2027.

The weakness ran through every major line. Tru Niagen sales of $23.3 million fell 10% year over year, a sharp reversal from 6% growth in Q2 and 21% in Q4 2025. Direct website sales, the company's strongest channel, grew 13% (17% adjusted), down from 23% in the prior quarter. Ingredient revenue fell to $3.8 million from $5.4 million in Q2 and $8.2 million in Q1, because a large ingredient customer is losing share to NMN and price-driven competitors. Distribution also suffered from Watson's order timing and the absence of a large healthcare-practitioner order. Total net sales have now declined for three straight quarters, from $33.8 million in Q4 2025 to $27.2 million. Gross margin slipped to 62.9% from 64.8% in Q2. Operating expenses rose to $18.7 million, with G&A up about $1.1 million year over year on litigation costs. Adjusted EBITDA stayed barely positive at $0.5 million, but that compares with $3.0 million in Q2 and $6.4 million a year ago.

The guidance trajectory may be the most telling development. At Q4 2025, management guided to 10%-15% total growth and reaffirmed that in Q1. In Q2, it narrowed the target to 10%-15% growth in e-commerce alone, with ingredients lower. In Q3, the release still calls for 15%-20% direct website growth, but overall e-commerce growth is now only about 5%. The company says the rest of the consumer business will offset that growth, and ingredients will be lower again. On the call, management guided only to a sequential improvement in Q4 and did not reiterate a full-year total figure. Expenses across S&M, R&D and G&A are guided higher into Q4. The tone also changed. Management cited "changing dynamics" and low-cost NMN competition, a step back from Q2's description of the "most exciting period in our history."

The catalyst list is long, and it is real:

• A lower-cost NR malate salt is completing qualification, with commercialization expected in early 2027. Management says it could cut COGS and help the ingredient business compete on price.
• Retail reach expanded to Walmart.com and roughly 300 GNC and Sam's Club locations, though with a single SKU.
• NanoCloud skincare is now permanent, and management reports strong early sales.
• Restore Hyper Wellness featured Niagen IV and injections across 200+ locations, and a ready-to-inject at-home kit launched in October.
• NB4168 began IND-enabling work with Evotec, targeting first-in-human dosing in 2027. A joint venture or separate financing for NAD Pharmaceuticals is possible.
• Mass General Brigham is planning a prevention trial of roughly 5,000 participants.
• China cross-border sales are now expected to reach 2-3x last year.
• The Elysium fee-award reversal removes a legal overhang.

Almost none of this, however, is in the current numbers. Management itself says Niagen Plus and skincare partnerships become meaningful contributors beginning in 2027.

The balance sheet buys time for that wait. Cash rose to $69.5 million from $66.7 million in Q2, with no debt, and the quarter generated $2.6 million of operating cash flow. Still, nine-month operating cash flow of $4.2 million compares with $12.8 million a year earlier. That gap shows the cash engine is weakening even as reserves grow.

The market had largely anticipated a difficult report. Shares closed at $2.36 on the eve of earnings, down 24.1% from the $3.11 open after the Q2 report and 39.3% below the 200-day moving average of $3.89. The stock sat just 2.2% above a 52-week low of $2.31, set the day before the release, after fading steadily from an August 27 high of $3.34. Investor sentiment was negative and essentially unchanged, edging from -0.333 to -0.326. The AVWAP reading remains negative. Expectations were already low, but this report offers little evidence that the decline in sales has bottomed.

The bottom line is that Niagen met a low EPS bar while the underlying business weakened on nearly every front. Revenue missed and fell for a third straight quarter, Tru Niagen turned negative, ingredients are losing ground to NMN, and full-year guidance has eroded call by call. Cash and a credible 2027 pipeline give the bull case substance. Until NR malate, Niagen Plus and the new retail channels show up in reported sales, though, bears have legitimate ammunition, and the stock's position near its lows reflects that.

Read our earnings preview for Niagen Bioscience, Inc.: https://www.earningswhispers.com/article/NAGE/21884

This earnings review was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.